APA (7th ed.) Citation

Kopanarov, V., Benisheva, T., Naydenova, R., Gergova, V., Dimitrov, D., Sidjimova, D., & Mateev, H. (2025). Safety profiles of biosimilars vs. their EU reference products: INNs (adalimumab, bevacizumab, trastuzumab, rituximab, infliximab, etanercept). Biotechnology & Biotechnological Equipment, 39(1), 1. https://doi.org/10.1080/13102818.2025.2529183

Chicago Style (17th ed.) Citation

Kopanarov, Valentin, Tatyana Benisheva, Radoslava Naydenova, Veska Gergova, Dimitar Dimitrov, Dobriana Sidjimova, and Hristo Mateev. "Safety Profiles of Biosimilars Vs. Their EU Reference Products: INNs (adalimumab, Bevacizumab, Trastuzumab, Rituximab, Infliximab, Etanercept)." Biotechnology & Biotechnological Equipment 39, no. 1 (2025): 1. https://doi.org/10.1080/13102818.2025.2529183.

MLA (9th ed.) Citation

Kopanarov, Valentin, et al. "Safety Profiles of Biosimilars Vs. Their EU Reference Products: INNs (adalimumab, Bevacizumab, Trastuzumab, Rituximab, Infliximab, Etanercept)." Biotechnology & Biotechnological Equipment, vol. 39, no. 1, 2025, p. 1, https://doi.org/10.1080/13102818.2025.2529183.